ArticleBMC infectious diseases2025
Elevated thrombosis-related biomarkers as predictors of disease severity and mortality in patients with severe fever with thrombocytopenia syndrome.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Standardized LDH-to-lymphocyte ratio improves early mortality prediction in severe fever with thrombocytopenia syndrome: A 15-day competing-risk bedside model.PLoS neglected tropical diseases · 2026Article
- Admission D-Dimer-to-Albumin Ratio as a Predictor of Poor Prognosis in Patients with Severe Fever with Thrombocytopenia Syndrome: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Early mortality risk prediction in severe fever with thrombocytopenia syndrome using an interpretable machine learning model based on routine clinical parameters.Frontiers in public health · 2026Article
- Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study explores the changes in thrombosis-related indicators in patients with severe fever with thrombocytopenia syndrome (SFTS), providing a basis for early diagnosis, treatment, and disease monitoring.
methodsThe patients were divided into mild and severe groups, as well as survivor and non-survivor groups. Forty-five healthy individuals were included as a control group. We compared the activity of thrombosis-related markers in these groups. The risk of developing severe disease and death in patients was predicted using receiver operating characteristic (ROC) curve analysis. We also examined the correlation between thrombomodulin (TM) and clinical lab parameters in the plasma of SFTS patients.
resultsComparison among the mild, severe, and healthy control groups revealed that the levels of TM, thrombin-antithrombin complex (TAT), plasmin-antiplasmin complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) were significantly higher in severe patients than in the healthy control group (P < 0.05). Comparison between the survivor and non-survivor groups showed that the levels of TM, TAT, and t-PAIC in the non-survivor group were higher than those in the survivor group, and the differences were statistically significant (P < 0.05). ROC analysis showed that TM had a higher predictive ability for the risk of severe disease (area under the ROC curve [AUROC] = 0.931). Additionally, TM (AUROC = 0.817) and t-PAIC (AUROC = 0.824) had higher predictive abilities for the risk of death. TM was positively correlated with thrombin time (TT), d-dimer (D-D), creatinine (CREA), total bile acid (TBA), and c-reactive protein (CRP), and negatively correlated with cholesterol (CHOL), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and platelet (PLT).
conclusionMonitoring thrombosis-related indicators in SFTS patients is crucial for assessing disease severity. Early symptomatic treatment can significantly reduce the rate of severe cases and prevent patient mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.